- Home
- ALLR vs CPHI Comparison
ALLR vs CPHI Comparison
Compare ALLR & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- CPHI
- Stock Information
- Founded
- ALLR 2004
- CPHI N/A
- Country
- ALLR United States
- CPHI China
- Employees
- ALLR N/A
- CPHI N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- CPHI Health Care
- Exchange
- ALLR Nasdaq
- CPHI Nasdaq
- Market Cap
- ALLR 4.0M
- CPHI 4.5M
- IPO Year
- ALLR N/A
- CPHI N/A
- Fundamental
- Price
- ALLR $0.82
- CPHI $0.24
- Analyst Decision
- ALLR
- CPHI
- Analyst Count
- ALLR 0
- CPHI 0
- Target Price
- ALLR N/A
- CPHI N/A
- AVG Volume (30 Days)
- ALLR 2.6M
- CPHI 657.7K
- Earning Date
- ALLR 05-13-2025
- CPHI 05-14-2025
- Dividend Yield
- ALLR N/A
- CPHI N/A
- EPS Growth
- ALLR N/A
- CPHI N/A
- EPS
- ALLR N/A
- CPHI N/A
- Revenue
- ALLR N/A
- CPHI $4,528,929.00
- Revenue This Year
- ALLR N/A
- CPHI N/A
- Revenue Next Year
- ALLR N/A
- CPHI N/A
- P/E Ratio
- ALLR N/A
- CPHI N/A
- Revenue Growth
- ALLR N/A
- CPHI N/A
- 52 Week Low
- ALLR $0.68
- CPHI $0.13
- 52 Week High
- ALLR $174.00
- CPHI $0.41
- Technical
- Relative Strength Index (RSI)
- ALLR 37.39
- CPHI 48.34
- Support Level
- ALLR $0.91
- CPHI $0.23
- Resistance Level
- ALLR $1.23
- CPHI $0.32
- Average True Range (ATR)
- ALLR 0.14
- CPHI 0.04
- MACD
- ALLR -0.02
- CPHI -0.00
- Stochastic Oscillator
- ALLR 3.15
- CPHI 21.50
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.